Pierre Deltenre

Pierre Deltenre

Auto-generated profile, based on publicly available information

Pierre Deltenre

Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2019 in Hepatology
Verified
Journal Article
Closed access
PDF file
FSFelix Stickel
Felix Stickel
PLPhilipp Lutz
Philipp Lutz
SBStephan Buch
Stephan Buch
HNHans Dieter Nischalke
Hans Dieter Nischalke
ISInes Silva
Ines Silva
MMMarsha Y. Morgan
Marsha Y. Morgan

11 January 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AMAstrid Marot
Astrid Marot
MDMargaux Dubois
Margaux Dubois
ETEric Trépo
Eric Trépo
CMChristophe Moreno
Christophe Moreno
PDPierre Deltenre
Pierre Deltenre
The rate of alcohol relapse among patients who underwent liver transplantation for alcoholic hepatitis (AH) is not precisely known. Synthesize the available evidence on liver transplantation for AH to assess alcohol relapse and 6-month survival. Meta-analysis of trials evaluating liver transplantation for AH, either clinically severe or diagnosed on the explant. Eleven studies were included. The pooled estimate rate for alcohol relapse was 0.22 (95% CI = 0.12–0.36) in overall analysis with high heterogeneity between studies (I2 = 76%), 0.20 (95% CI = 0.07–0.43) in the subgroup analysis including patients with clinically severe AH (I2 = 84%), 0.14 (95% CI = 0.08–0.23) among patients with clinically severe AH in sensitivity analysis excluding the discrepant studies that did not use stringent selection criteria for liver transplantation (I2 = 0%), and 0.15 (95% CI = 0.07–0.27) for recurrent harmful alcohol consumption among patients with clinically severe AH (I2 = 3%). The risk of alcohol relapse was not different between AH transplanted patients and patients with alcoholic cirrhosis who underwent elective liver transplantation in sensitivity analysis excluding the discrepant studies (OR = 1.68, 95%CI = 0.79–3.58, p = 0.2, I2 = 16%). The pooled estimate rate for 6-month survival was 0.85 (95% CI = 0.77–0.91, I2 = 49%), and 0.80 among patients transplanted for clinically severe AH (95% CI = 0.69–0.88, I2 = 30%). AH transplanted patients had similar 6-month survival to patients with alcoholic cirrhosis who underwent elective liver transplantation (OR = 2.00, 95% CI = 0.95–4.23, p = 0.07, I2 = 0%). Using stringent selection criteria, 14% of patients with clinically severe AH have alcohol relapse after liver transplantation. The percentage of alcohol relapse of AH transplanted patients is similar than that of patients who underwent elective liver transplantation.

1 September 2016 in Journal of Hepatology
Verified
Journal Article
Closed access
HVHélène Vandenbulcke
Hélène Vandenbulcke
CMChristophe Moreno
Christophe Moreno
ICIsabelle Colle
Isabelle Colle
JKJean-François Knebel
Jean-François Knebel
SFSven M Francque
Sven M Francque
PDPierre Deltenre
Pierre Deltenre

6 December 2016 in Liver International
Verified
Journal Article
Closed access
PDF file
AMAstrid Marot
Astrid Marot
ETEric Trépo
Eric Trépo
CDChristopher Doerig
Christopher Doerig
ASAlain Schoepfer
Alain Schoepfer
CMChristophe Moreno
Christophe Moreno
PDPierre Deltenre
Pierre Deltenre

20 June 2022 in Hepatology
Verified
Journal Article
Closed access
PDPierre Deltenre
Pierre Deltenre
Alberto ZanettoAlberto Zanetto
Alberto Zanetto
DSDario Saltini
Dario Saltini
CMChristophe Moreno
Christophe Moreno
FSFilippo Schepis
Filippo Schepis

27 October 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AMAstrid Marot
Astrid Marot
JHJean Henrion
Jean Henrion
JKJean-François Knebel
Jean-François Knebel
CMChristophe Moreno
Christophe Moreno
PDPierre Deltenre
Pierre Deltenre
Cirrhosis is a heterogeneous clinical condition that includes patients at wide-ranging stages of severity. The role of the underlying liver disease on patient prognosis remains unclear. To assess the impact of the underlying liver disease on the occurrence of hepatocellular carcinoma (HCC) and death. Data related to the occurrence of HCC and death were collected during a 21-year period among patients with cirrhosis related to alcoholic liver disease (ALD) (n = 529), chronic hepatitis C virus (HCV) infection (n = 145) or non-alcoholic fatty liver disease (NAFLD) (n = 78). At inclusion, ALD patients were younger than HCV and NAFLD patients (56 vs. 67 vs. 63 years; p<0.001) and had worse liver function (percent of patients with Child-Pugh stages B or C: 48% vs. 8% vs. 17%; p<0.001). During follow-up, 85 patients developed HCC and 379 died. The 10-year cumulative incidence rate of HCC was lower in ALD patients than in HCV and NAFLD patients (8.4% vs. 22.0% vs. 23.7%; p<0.001). The 10-year cumulative incidence rates of mortality were not statistically different between ALD, HCV and NAFLD patients (58.1% vs. 47.7% vs. 49.9%; p = 0.078). Alcohol abstinence and viral eradication were associated with reduced mortality among ALD and HCV patients, respectively. In multivariate analyses, ALD was associated with a reduced risk of HCC (0.39; 95% CI, 0.20–0.76; p = 0.005) but with a higher risk of mortality (1.53; 95% CI, 1.20–1.95; p<0.001). ALD patients died more frequently from decompensation of cirrhosis. Despite a lower incidence of HCC, patients with ALD-related cirrhosis have a worse outcome than those with chronic HCV infection or NAFLD-related cirrhosis.